Trial Information
Plus Therapeutics is evaluating REYOBIQ™ (rhenium Re186 obisbemeda), a novel radiotherapy for patients with Leptomeningeal Metastases.
Watch now to learn more.
Patient Eligibility
Only a qualified healthcare professional can determine whether or not you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician. Full patient eligibility will be discussed upon patient screening.
Age Range
Adults, 18 years and older
Condition
Leptomeningeal Metastases from any solid tumor cancers (i.e. breast, lung, melanoma, gastrointestinal)
Prior Treatment
No prior whole brain or spinal cord radiation therapy
Informed Consent
Able to understand the study purposes and risks
Gender
All; Women have negative pregnancy test at screening; Subjects must use effective contraception during study
Principal Investigators
There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.
Andrew Brenner, M.D., Ph.D.
UT Health San Antonio, Mays Cancer Center
San Antonio, Texas
Previously Enrolled
as part of the ReSPECT-LM single-dose clinical trial:
Michael Youssef, M.D.
UT Southwestern Medical Center
Priya Kumthekar, M.D.
Northwestern Memorial Hospital
Michael Schulder, M.D.
North Shore University Hospital
Pierre Giglio, M.D.
The Ohio State University Cancer Center
Randy S. D’Amico, M.D.
Lenox Hill Hospital
Trial Locations
Please visit this website regularly for updates as new locations are added.
UT Health Science Center
San Antonio
Previously Enrolled
as part of the ReSPECT-LM single-dose clinical trial:
UT Southwestern Medical Center – Dallas
Northwestern Memorial Hospital – Chicago
North Shore University Hospital – New York
Ohio State University – Columbus
Lenox Hill Hospital – New York
What Can You Do Next?
Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.
Discuss With Your Physician
Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your physician first.
Print, save, or email this page to your physician to discuss at your next visit
Contact A Trial Coordinator
A trial coordinator is a specialized researcher who supports the management and coordination of clinical research studies. If you are interested in participating in a clinical trial, you may call a trial coordinator directly at one of the trial locations below.
UT Health Science Center
San Antonio
Leticia Velten
210-450-1921
velten@uthscsa.edu
Contact Us
Request More Information
News
August 13, 2024
August 12, 2024
July 25, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
July 2, 2024
June 7, 2024
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
May 9, 2024
Publications
Posters
Presentations
Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM), SNO/ASCO CNS Metastases Conference Oral Presentation, August 8, 2024
Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases, SNO/ASCO CNS Metastases Independent Symposium, August 8, 2024
Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials, Gordon Research Conference, July 8, 2024
Phase 1A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM), Cancer Prevention & Research Institute of Texas (CPRIT) Innovations Conference, October 3, 2023
KOL Roundtable on Leptomeningeal Metastases: An Obvious Disease Target for Radiotherapeutic Intervention, SNO/ASCO CNS Cancer Conference, August 11, 2023
Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial, EANM Congress, October 19, 2022
Resources
Note: all external links
- American Brain Tumor Association
- American Cancer Society
- Brain Tumor Network
- Dictionary of Cancer Terms
- End Brain Cancer Initiative
- MedlinePlus (NIH)
- National Brain Tumor Society
- National Cancer Institute
- National Comprehensive Cancer Network
- Support Groups Listing
- The Brain Tumour Charity
- Trial Connect
- VirtualTrials.com
- Voices Against Brain Cancer
Updates
LM ODD for Lung Cancer Patients
FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Lung Cancer Patients with Leptomeningeal Metastases We are thrilled to announce that the U.S. FDA has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of...
#RareDiseaseDay2025
Shining a Light on Rare Diseases: Raising Awareness Together At Plus Therapeutics, we are committed to advancing research and innovative treatments for rare and challenging diseases. Today, on Rare Disease Day, we stand with patients, caregivers, and advocates...
ReSPECT-LM Phase 1 Single Dose Completed
BREAKING NEWS: ReSPECT-LM Phase 1 Single Dose Completed – Phase 2 Dose Determined We are thrilled to announce a major milestone in the ReSPECT-LM clinical trial! The Phase 1 single-dose portion of the trial is now complete, and the recommended Phase 2 dose (RP2D) for...
CNSide Diagnostics Leadership Appointments
Plus Therapeutics Announces Key Leadership Appointments for CNSide Diagnostics, LLC We are excited to announce the appointment of Russell Bradley as President and General Manager of CNSide Diagnostics, LLC, a Plus Therapeutics subsidiary focused on advancing...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Contents
- 1 You Deserve Every Option.
- 2 See if You Qualify for our Leptomeningeal Metastases Clinical Trial
- 2.1 Trial Information
- 2.2 Patient Eligibility
- 2.3 Principal Investigators
- 2.4 Trial Locations
- 2.5 What Can You Do Next?
- 2.6 Contact A Trial Coordinator
- 2.7 Contact Us
- 2.8 Request More Information
- 2.9 News
- 2.10 Publications
- 2.11 Resources
- 2.12 Updates
- 2.13 LM ODD for Lung Cancer Patients
- 2.14 #RareDiseaseDay2025
- 2.15 ReSPECT-LM Phase 1 Single Dose Completed
- 2.16 CNSide Diagnostics Leadership Appointments
- 2.17 No Results Found